anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Effective follow-up and management of elderly post-CABG patients is important in the overall recovery process. Specifically, this study will attempt to bridge the gap in current literature related to the impact of follow-up interventions to enhance recovery outcomes in the CABG population. The major purpose of this experimental study is to test the effects of the symptom management home care nursing intervention (SMHCNI) on recovery outcomes of elderly CABG patients using a randomized, two group (N=284) repeated measures design with measurements at discharge, at 3 and 6 weeks, and 3 and 6 months post- operatively. One group will receive the intervention and routine care (RC) and the other group will receive only RC. The major aim will be to determine if the intervention group will demonstrate: better physiological functioning (decreased symptom interference on physical functioning (decreased symptom interference on physical functioning; better scores on the SF 36 subscales: physical, role-physical and vitality, and increased activity and exercise energy expenditure); better physiological conditioning (decreased symptom interference on physical functioning; better scores on the SF 36 subscales; role-emotional, social, mental, and vitality); and fewer post-operative problems (e.g., infections, fluid in lungs, heart rate rhythm problems). Additional outcomes for secondary aims are: lower levels of health care utilization \[HCU\] (i.e., fewer number of visits to health care providers, fewer number of emergency department visits, fewer number of home health visits, fewer rehospitalizations); and higher patient satisfaction (with level of functioning and care received). In addition this study will examine the potential effects of mediating (evaluation of level of functioning and care received)\> In addition this study will examine the potential effects of mediating (evaluation of level of functioning and care received). In addition this study will examine the potential effects of mediating (evaluation of symptoms, and perceived self-efficacy, and moderating variables (participation in cardiac rehabilitation) with the intervention on outcomes identified above. The intervention will be delivered using a device called the Health Buddy that is attached to the patient's telephone line, able to download to a free secure Internet site daily, and cannot be used by health care providers for post-hospital follow up care. The 6- week SMHCNI was designed using Bandura's (1986) definition of self- efficacy which is to enhance the beliefs in ones capabilities to organize and execute the sources and actions required to manage prospective situations. Preliminary data have shown that these patients are going home with symptom management problems, but that complications arising from these problems might be prevented with early detection and management. Using a follow-up intervention such as the SMHCNI is expected to result in better functioning, management of symptoms and fewer post-operative problems. Also, a better understanding of HCU, patient satisfaction, and self-efficacy as variables will be described.
BACKGROUND Leukocytoclastic vasculitis (LCV) is an atypical form of cutaneous paraneoplastic manifestation. Its association with multiple myeloma (MM) is even rarer and is associated with poor prognosis and short survival, regardless of the therapy instituted. Different treatment approaches are necessary. We present a case in which LCV was the first manifestation of MM, and high-intensity laser therapy (HILT) was used as an option to accelerate healing and control pain. CASE REPORT A 76-year-old woman presented with pain and paresthesia in her lower limbs, associated with palpable purpura. The clinical diagnosis was small-vessel vasculitis. Laboratory tests showed an elevated gamma globulin monoclonal peak on protein electrophoresis. The immunophenotypic study of bone marrow aspirates led to the diagnosis of MM. Due to pain refractory to conventional analgesics, and the progressive evolution of the lesions, despite corticosteroid therapy, we performed photo-biomodulation with a neodymium-doped yttrium aluminum garnet laser (Nd: YAG), wavelength 1064 nanometers, using a 7-mm probe and energy density 6 J/cm². After the first session, the patient was referred for pain management, and after 5 weeks, we observed complete healing in ulcerated lesions and involution of bullous lesions. CONCLUSIONS This case report shows the positive effects of the Nd: YAG laser in modulating healing and reducing pain. HILT is an innovative, non-invasive, and effective treatment and should be considered a promising technique to accelerate healing and controlling pain.
Vivaglobin: 16% (160 mg/mL) liquid formulation of human IgG for SC use. Loading dose: 100 mg/kg for 5 consecutive days; maintenance dose: 100 mg/kg 1 to 2 times a week for 24 weeks.
A method for making microcapsules including an encapsulated material may include providing, in an aqueous continuous phase, one or more microcapsules including an encapsulated material surrounded by an inner shell including a first cross-linked polymer matrix. An outer surface of the inner shell may be hydrophobic. The method may also include adding thereto a polymerizable liquid component and a stabilizing agent, wherein the polymerizable liquid component is immiscible in the aqueous environment. The method may also include forming microcapsules wetted by the polymerizable liquid component. The method may further include polymerizing the polymerizable liquid component forming an outer shell including a second cross-linked polymer matrix formed about the inner shell. The microcapsules may be included in articles and compositions.
As a primitive driving force for biological reproduction, sexual behavior (and its associated mechanisms) is extremely complex, and orgasm plays an essential role. The limbic system plays a very important role in regulating human sexual behavior. However, it is not clear which components of the limbic system are related to orgasm sensation. We studied a rare case of spontaneous orgasmic aura in a male patient with temporal lobe epilepsy. Stereoelectroencephalography (SEEG) revealed that the right amygdala was the origin of orgasmic aura. Surgical removal of the medial temporal lobe, including the right amygdala, completely eliminated the patient's seizures. This study demonstrates the critical role of the amygdala in human male orgasm.
An RFID-enabled storage container and systems and methods for assembly and use thereof. The RFID-enabled storage container may include adjustable shelving with built-in antennas, such that the shelving may be customized as may be needed. The system may include a storage container, an inventory management system, and one or more point of use terminals. The storage container may identify and check inventory stored thereon, and provide such information to the inventory management system. The storage container may notify the inventory management system when a product is no longer detected within its inventory, and the inventory management system may monitor the one or more point of use terminals to determine if the undetected product has been used at one of the point of use terminals. The inventory management system may also predict inventory needs as well as maintain age and other data for inventory and provide feedback via an illumination indication.
Disclosed is a portable device for collecting and processing continuous monitoring data. The device has a data interface configured to receive a stream of continuous monitoring data from a body-worn sensor, the continuous monitoring data being indicative of an analyte in a bodily fluid. A control is connectable to the data interface. The control controls a first mode of operation during which configuration parameters are established in response to receiving a start signal indicating a sensor session start of the body-worn sensor. The control also controls a second mode of operation during which the continuous monitoring data is collected and processed and also controls the switching from the first mode to the second mode. The control blocks further starting of the first mode for a remaining sensor session time after the switching to the second mode of operation. Also disclosed are a related medical system, method and computer program product.
A substance for poxvirus molluscum infection treatment that includes a mixture of Anacardium occidentale seeds and sunflower oil is disclosed. The mixture is obtained by the washing, drying, and grinding of at least seven Anacardium occidentale seeds. The grinded seeds are then mixed in with at least one cup of sunflower oil. The mixture is then heated under a low temperature for a duration of at least ten minutes until the seeds are in a liquid or semi-liquid state. The temperature is then raised when the mixture begins to change color. The temperature is then lowered once the mixture ceases to produce smoke. The mixture is then strained and poured into sterile bottles which are wrapped in aluminum foil. When applied to a user, the mixture is then placed on a patch which is then placed on an infected area of a user's body.
1,167,173. Cosmetic aerosols. J. G. SPITZER and M. SMALL. 30 Sept.. 1966 [1 Oct., 1965], No. 43688/66. Heading A5B. An aerosol astringent and anti-perspirant composition comprises an astringent in fine powder form dispersed in a liquid vehicle which is substantially anhydrous, the liquid vehicle containing a liquified propellant and a non-volatile non-hygroscopic liquid, the astringent being in an inactive state when in dry powder form but which in the presence of moisture is converted to an anti-perspirant active form in which the astringent is present in an amount of from 0.2 to 10% by weight, and in which the non-volatile, non-hygroscopic liquid is present in an amount from 2 to 50% by weight of the total composition. Examples of suitable astringents include zinc chloride, zinc sulphate, zinc sulphocarbolate, aluminium sulphate, aluminium chloride, aluminium sulphocarbolate, aluminium chlorohydrate, ferric chloride, zirconium tetrachloride, and zirconium sulphate. The non-volatile, non- hygroscopic liquid may be a hydrocarbon oil such as tetradecane, an ester such as isopropyl myristate or glyceryl trioliate, an alcohol such as lauryl alcohol, a carboxylic acid such as oleic acid, or a dimethyl polysiloxane. The propellant may be a fluorinated hydrocarbon, propane, butane, pentane or isobutane. Optional ingredients include colloidal silica, perfume. and bactericides such as hexachlorophene.
A 75 mg REL-1017 loading dose (three 25 mg REL-1017 tablets) will be administered on Day-1 of the 28-day treatment period. From Day-2 to Day-28, participants will take 25 mg REL-1017 in addition to their ongoing antidepressant.
FIELD: medicine, particularly, stomatology. SUBSTANCE: tooth paste contains synthetic amorphous silicon dioxide, cleaned sodium carboxymethylcellulose, distilled glycerin PK-94 and sorbitol, fluorine sodium, sodium food benzoate, saccharine, pigmentary titanium dioxide, sodium laurylsulphate, aromatic composition, water, and additionally calcium gluconate. All the components are taken in preset quantitative ratio. The tooth paste is safe for health, removes dental deposit, strengthens tooth enamel and protects against caries. EFFECT: higher efficiency. 2 tbl
Reelin, a large extracellular glycoprotein, plays critical roles in neuronal development and synaptic plasticity in the central nervous system (CNS). Recent studies have revealed non-neuronal functions of plasma Reelin in inflammation by promoting endothelial-leukocyte adhesion through its canonical pathway in endothelial cells (via ApoER2 acting on NF-κB), as well as in vascular tone regulation and thrombosis. In this study, we have investigated the safety and efficacy of selectively depleting plasma Reelin as a potential therapeutic strategy for chronic inflammatory diseases. We found that Reelin expression remains stable throughout adulthood and that peripheral anti-Reelin antibody treatment with CR-50 efficiently depletes plasma Reelin without affecting its levels or functionality within the CNS. Notably, this approach preserves essential neuronal functions and synaptic plasticity. Furthermore, in mice induced with experimental autoimmune encephalomyelitis (EAE), selective modulation of endothelial responses by anti-Reelin antibodies reduces pathological leukocyte infiltration without completely abolishing diapedesis. Finally, long-term Reelin depletion under metabolic stress induced by a Western diet did not negatively impact the heart, kidney, or liver, suggesting a favorable safety profile. These findings underscore the promising role of peripheral anti-Reelin therapeutic strategies for autoimmune diseases and conditions where endothelial function is compromised, offering a novel approach that may avoid the immunosuppressive side effects associated with conventional anti-inflammatory therapies.
Spinal anesthesia is used for operation with epidural patient-controlled device for pain control. Bupivacaine Hcl 0.5% Inj. 9-10mg is injected into intrathecal space for anesthesia. 0.2% ropivacaine is used for postoperative pain control with continuous infusion into epidural space.
The invention relates to a new gene Lt9.1 of P-superfamily conotoxins of signal conus collected form South China Sea, a polypeptide sequence 1t9a coded by the same and applications of the polypeptide in the researche of neurobiology and ion channel as well as in the development of analgesics. The invention provides a new gene Lt9.1 of P-superfamily conotoxins found in a poison canal of signal conus from South China Sea. The cDNA sequence of the gene is shown in a sequence list as and 1t; 400 and gt; 1 sequence. The amino acid sequence of the precursor of the polypeptide(conotoxin 1t9a) coded by the gene is shown in the sequence list as and 1t;400 and gt; 2 sequence. The invention obtains a 1t9a mature peptide from crude conotoxins of the signal conus through separation and purification, the amino acid sequence of which is shown in the sequence list as and 1t;400 and gt;3 sequence. Deactivation of TTX-resistant sodium channels can be delayed obviously, and the cell inward sodium current is increased, provided the concentration of the conotoxin 1t9a is below 500nM. The conotoxin 1t9a also has analgesic effect on central nervous system and can be used as a probe to identify the classes and subclasses of ion channels, or in the research and development of tool dugs and preparation of analgesic drugs.
PROBLEM TO BE SOLVED: To obtain the subject composition causing no sticking to a tablet machine in spite of containing hygroscopic sugar alcohol powders, and directly compressible, by including at least a specific amount of a hygroscopic sugar alcohol and a specific sucrose fatty acid ester. SOLUTION: This composition is obtained by including (A) >=50 wt.% of a hygroscopic sugar alcohol having a weight increment of >=1 wt.% at 75% relative humidity for 24 h, (pref. sorbitol or maltitol) and (B) a sucrose fatty acid ester a melting starting point of which is >=50 deg.C (e.g. sucrose behenate ester). It is desirable to use a powdery material consisting mainly of a pulverized material as the component B, and desirable to use a powery material containing >=50 wt.% of finely pulverized material with a particle diameter of <=20 μm. The content of the component B in this composition is pref. 1 to 2 wt.%.
PURPOSE: To obtain a mouth-washing composition excellent in dispersion stability of an abrasive and having an easily acting and a sufficient and necessary degree of cleaning power by adding a specific polysaccharide to a mouth-washing composition composed of a specified amount of an abrasive and having a specific viscosity. CONSTITUTION: Gellan gum is added to a mouth-washing composition composed of 2-30wt.% of an abrasive and having a viscosity of 1-1800cp at 25 deg.C. Gellan gum is preferably added in an amount of 0.005-1wt.% based on the total of the composition. The abrasive is e.g. a precipitated silica, zirconosilicate, calcium phosphate and aluminum hydroxide. Gellan gum is a polysaccharide produced by a bacterium, Pseudomonas elodea, and the constituting saccharides are glucose, glucuronic acid and rhamnose, those molecular ratios are 2:1:1.
Two randomized, multi-center, double-blind trials (Study 1 and Study 2) compared the incidence of gastric ulcer formation in 428 patients taking naproxen and esomeprazole magnesium delayed-release tablets and 426 patients taking enteric-coated naproxen. Subjects were at least 18 years of age with a medical condition expected to require daily NSAID therapy for at least 6 months, and, if less than 50 years old, with a documented history of gastric or duodenal ulcer within the past 5 years. The majority of patients were female (67%), white (86%). The majority of patients were 50-69 years of age (83%).

Studies 1 and 2 showed that naproxen and esomeprazole magnesium delayed-release tablets given as 500 mg/20 mg twice daily statistically significantly reduced the 6-month cumulative incidence of gastric ulcers compared to enteric-coated naproxen 500 mg twice daily (see Table 6). 

The results at one month, three months, and six months are presented in Table 6.

In these trials, patients receiving naproxen and esomeprazole magnesium delayed-release tablets had a mean duration of therapy of 152 days compared to 124 days in patients receiving enteric-coated naproxen alone. A higher proportion of patients taking EC-naproxen (12%) discontinued the study due to upper GI adverse events (including duodenal ulcers) compared to naproxen and esomeprazole magnesium delayed-release tablets (4%) in both trials [see Adverse Reactions (6)] . 

The efficacy of naproxen and esomeprazole magnesium delayed-release tablets in treating the signs and symptoms of osteoarthritis was established in two 12-week randomized, double-blind, placebo-controlled trials in patients with osteoarthritis (OA) of the knee. In these two trials, patients were allowed to remain on low-dose aspirin for cardioprophylaxis. Naproxen and esomeprazole magnesium delayed-release tablets was given as 500 mg/20 mg twice daily. In each trial, patients receiving naproxen and esomeprazole magnesium delayed-release tablets had significantly better results compared to patients receiving placebo as measured by change from baseline of the WOMAC pain subscale and the WOMAC physical function subscale and a Patient Global Assessment Score.

Based on studies with enteric-coated naproxen, improvement in patients treated for rheumatoid arthritis was demonstrated by a reduction in joint swelling, a reduction in duration of morning stiffness, a reduction in disease activity as assessed by both the investigator and patient, and by increased mobility as demonstrated by a reduction in walking time. In patients with osteoarthritis, the therapeutic action of naproxen has been shown by a reduction in joint pain or tenderness, an increase in range of motion in knee joints, increased mobility as demonstrated by a reduction in walking time, and improvement in capacity to perform activities of daily living impaired by the disease. In patients with ankylosing spondylitis, naproxen has been shown to decrease night pain, morning stiffness and pain at rest.
This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
AIM: The purpose of this study was to interpret real-world clinical data to analyze the surgical safety and survival outcomes of patients with initial unresectable hepatocellular carcinoma (uHCC) after conversion therapy.
METHODS: A retrospective analysis was performed on 2984 hepatocellular carcinoma (HCC) patients hospitalized in Shandong Cancer Hospital Affiliated to Shandong First Medical University from June 1st, 2019 to June 1st, 2023. Clinicopathological features, response to systemic and/or loco-regional treatments, surgical resection rate after conversion therapy, surgical safety, and postoperative recurrence were analyzed.
RESULTS: A total of 38 patients were successfully converted to obtain surgical resection. 35 patients underwent radical resection. A high objective response rate (ORR) (52.6% under RECIST v1.1 and 78.9% under mRECIST criteria) was observed in patients under conversion therapy, and the disease control rate (DCR) was 100%. Pathologic complete response (pCR) was 42.9%. Treatment-related adverse events (TRAEs) of any grade were observed in 37 patients (97.4%). Safety of conversion or direct surgery continues to improve. The median follow-up time was 19.3 months. The 1-year Disease-free survival (DFS) rate of patients with direct surgery and patients with conversion surgery were 91.4% and 86.8%, respectively.
CONCLUSIONS: With conversion therapy, a small percentage (1.81%) of uHCC patients are likely to be converted to radical resection. Local combined systemic therapy is a relatively safe and effective conversion therapy, and the safety of surgery is gradually improved after successful conversion. Preliminary follow-up data showed satisfactory survival benefits for patients undergoing conversion surgery.
TRIAL REGISTRATION: This was a retrospective study and it did not interfere with treatment decisions.
PURPOSE OF REVIEW: Treatment of cardiogenic shock remains largely driven by expert consensus due to limited evidence from randomized controlled trials. In this review, we aim to summarize the approach to the management of patients with cardiogenic shock in the ICU prior to mechanical circulatory support (MCS).
RECENT FINDINGS: Main topics covered in this article include diagnosis, monitoring, initial management and key aspects of pharmacological therapy in the ICU for patients with cardiogenic shock.
SUMMARY: Despite efforts to improve therapy, short-term mortality in patients with cardiogenic shock is still reaching 40-50%. Early recognition and treatment of cardiogenic shock are crucial, including early revascularization of the culprit lesion with possible staged revascularization in acute myocardial infarction (AMI)-CS. Optimal volume management and vasoactive drugs titrated to restore arterial pressure and perfusion are the cornerstone of cardiogenic shock therapy. The choice of vasoactive drugs depends on the underlying cause and phenotype of cardiogenic shock. Their use should be limited to the shortest duration and lowest possible dose. According to recent observational evidence, assessment of the complete hemodynamic profile with a pulmonary artery catheter (PAC) was associated with improved outcomes and should be considered early in patients not responding to initial therapy or with unclear shock. A multidisciplinary shock team should be involved early in order to identify potential candidates for temporary and/or durable MCS.
Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
The invention discloses powder-filled hydrogel. The powder-filled hydrogel is prepared from, by mass, 0.5 part of powder, 0.05-0.5 part of gelator and 5-20 parts of solvent. The powder is prepared from plant powder for cosmetics, pearl powder and inorganic particles for cosmetics. The gelator is obtained by mixing one or more of sodium polyacrylate, sodium carboxymethylcellulose, carboxymethyl cellulose sodium, polyacrylic acid copolymer, sodium alga acid and Carbomer. The gelator is free of toxicity, safe, low in price and free of pollution and facilitates the application and popularization of the gel product. The powder-filled hydrogel is high in stability, free of delamination, easy to store, easy to absorb and good in smear feeing and can be widely applied to the field of cosmetics.